The first GLP-RA, twice-daily exenatide, was approved in the USA in 2005 [3] and, most recently, semaglutide received approval for administration by injection in 2017 [4] and in an oral formulation in 2019 [5]
NAC can also cause strange immunological side effects
BBB and BSCB disruption facilitate CNS infiltration of immune cells, including T cells, macrophages, and neutrophils, culminating in multifocal demyelination and neurodegeneration [143]
This cellular damage contributes to clinical sequelae such as prolonged mechanical ventilation dependence and surfactant deficiency (76)
"Carnitine levels in epileptic children." J Child Neurol 1998;13:546-9
Before starting semaglutide, understanding what the medication can and cannot do helps set appropriate expectations